Free Trial
NYSE:AGN

Allergan (AGN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$191.64
$193.38
50-Day Range
$184.04
$193.89
52-Week Range
$114.27
$202.21
Volume
12.44 million shs
Average Volume
4.01 million shs
Market Capitalization
$63.50 billion
P/E Ratio
N/A
Dividend Yield
1.53%
Price Target
N/A
AGN stock logo

About Allergan Stock (NYSE:AGN)

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

AGN Stock News Headlines

30 Most Miserable Countries in the World
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
See More Headlines
Receive AGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/10/2020
Today
7/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
CUSIP
01849010
Fax
N/A
Employees
17,400
Year Founded
N/A

Profitability

Net Income
$-5,271,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.09 billion
Cash Flow
$36.70 per share
Book Value
$177.28 per share

Miscellaneous

Free Float
N/A
Market Cap
$63.50 billion
Optionable
Optionable
Beta
1.20
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Should I Buy Allergan Stock? AGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Allergan plc:

  • Allergan plc has a diverse portfolio of products in various therapeutic areas, including medical aesthetics, dermatology, eye care, neuroscience, and more, providing a wide revenue stream.
  • The company is actively involved in developing innovative treatments for various conditions, such as therapies for non-alcoholic steatohepatitis, autoimmune disorders, and neurodegenerative disorders like Alzheimer's disease, which could lead to significant market opportunities.
  • Allergan plc has strategic collaborations and licensing agreements with reputable companies like Editas Medicine, Inc., enhancing its research and development capabilities and potential for future growth.
  • The company's recent stock price performance has shown resilience and potential for growth, making it an attractive investment opportunity in the pharmaceutical industry.
  • Allergan plc's focus on regenerative medicine products and gene therapy, such as RST-001 for retinitis pigmentosa, demonstrates its commitment to cutting-edge technologies that could drive long-term value for investors.

Cons

Investors should be bearish about investing in Allergan plc for these reasons:

  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Allergan plc's product development timelines and market access.
  • Market volatility and economic uncertainties may affect the company's revenue streams and profitability, leading to potential fluctuations in stock performance.
  • Allergan plc's dependency on a few key products or therapies for a significant portion of its revenue poses a risk in case of market shifts or patent expirations.
  • Investing in pharmaceutical companies involves inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new products, which could impact Allergan plc's financial performance.
  • Changes in healthcare policies and pricing regulations globally may impact Allergan plc's profitability and market positioning, adding a level of uncertainty for investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 30, 2024. Please send any questions or comments about these Allergan pros and cons to contact@marketbeat.com.

AGN Stock Analysis - Frequently Asked Questions

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings data on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The firm's revenue for the quarter was up 6.6% on a year-over-year basis.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU) and Aegean Marine Petroleum Network (ANW).

This page (NYSE:AGN) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners